SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: $Mogul who wrote (61637)1/12/2000 6:37:00 PM
From: StoxRider  Read Replies (2) of 108040
 
Princeton, New Jersey, Jan. 7 (Bloomberg Data) -- Isis Pharmaceuticals
Inc. (ISIP US) was reiterated short-term ``outperform' by analyst Jeffrey J.
Kraws at Gruntal & Co. The long-term rating was also reiterated
'outperform.' The short-term and long-term price targets are $43 and
$52 per share, respectively.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News